Coventry First Advocates for Transparency in Life Settlements
Coventry First Advocates for Transparency in Life Settlements
Urges transparency on life expectancy accuracy
Following Lapetus's imminent closure, argues elimination of any claim to trade secret protection
Coventry First LLC, a leading entity in the life settlements market, has recently issued a legal statement in response to Lapetus Solutions, Inc.'s attempt to keep essential life expectancy audit reports from being publicly disclosed. Coventry firmly believes that transparency is crucial, not only for maintaining the integrity of the life settlement market but also for ensuring that all stakeholders, including investors and regulators, have access to accurate life expectancy estimates.
The life expectancy audit reports in question are mandated by state law and must be submitted every three years to Florida's Office of Insurance Regulation (OIR). These reports play a significant role in assessing the accuracy of life expectancy predictions made in prior assessments. Coventry argues that these reports lack any proprietary methodologies and should not be protected as trade secrets. Furthermore, Lapetus has publicly advertised its life expectancy accuracy through various marketing avenues, undermining its claim to confidentiality.
Alan H. Buerger, the Executive Chairman of Coventry, has emphasized the need for reliable predictions in the life settlement industry. He states, "Investors and regulators alike need confidence that life expectancy estimates are accurate, reliable, and compliant with actuarial standards. Transparency protects investors and the integrity of the entire life settlement market." Coventry's response reflects its commitment to advocating for consumer rights and enhancing regulatory standards within the industry.
Lapetus's Imminent Closure Should Make Trade Secret Claims Moot
Lapetus’s recent announcement, via its CEO Dr. S. Jay Olshansky, confirming the cessation of its business operations, raises questions regarding their claims to protect certain information as trade secrets. According to Coventry, once Lapetus ceases its business activities, the statutory definition of a trade secret—specifically its relevance in operational procedures and competitive advantage—loses its validity. Therefore, they assert that disclosure of the requested audit results is warranted and legally justifiable.
Importance of Accurate Life Expectancies
The implications of this legal dispute extend far beyond court proceedings; they touch on the very foundation of life settlements. Life expectancy estimates are critical for determining the value of life insurance policies within this niche market. If estimates frequently fall short, it could lead to misguided investor expectations, significant financial losses, and an erosion of confidence throughout the sector.
Coventry's Executive Chairman reiterates this concern, noting, "Independent academic reviews have shown that Lapetus's life expectancies were found to be shorter in over 80% of tested cases, yielding an actual-to-expected ratio of only 31%. This stands in stark contrast to the 96.3% accuracy rate that Lapetus has publicly claimed." This disparity highlights the necessity for stringent auditing and accurate reporting within the life expectancy sphere.
Looking back, Florida regulators have implemented rigorous measures following the infamous Mutual Benefits fraud, which revealed the catastrophic consequences of unverified life expectancy estimates. This event catalyzed changes in legislation requiring that all life expectancy providers be registered and regularly disclose their findings to the OIR, ensuring that such errors are not repeated.
About Coventry
Coventry stands as a pioneering force in the secondary market for life insurance. With over 20 years of experience, the company has significantly advanced the industry while creating opportunities for policy owners. Coventry’s unwavering commitment to consumer rights distinguishes it as a leader in setting industry standards and improving consumer options. To date, it has facilitated over $6 billion in benefits to policy owners no longer needing their insurance policies. For more information about Coventry and its initiatives, please visit Coventry.com.
Frequently Asked Questions
What is the main focus of Coventry's legal response?
The main focus is advocating for transparency in life expectancy audits to ensure market integrity and investor confidence.
Why does Coventry believe Lapetus's claims are not valid?
Coventry argues that Lapetus's imminent closure eliminates any valid claim to protect information as trade secrets.
How do inaccurate life expectancies affect investors?
Inaccurate estimates can lead to misleading valuations, resulting in significant financial losses for investors and a decline in market confidence.
What historical event prompted regulatory changes in Florida?
The Mutual Benefits fraud case highlighted the risks of unverifiable life expectancy estimates, leading to stronger regulatory measures.
What is Coventry's role in the life insurance market?
Coventry is the leader in the secondary market for life insurance, promoting consumer rights and establishing industry standards for over two decades.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.